FDA Rejects Xeljanz Expanded Use for Plaque Psoriasis

Article

Pfizer asked to provide additional safety analyses for proposed indication.

Pfizer asked to provide additional safety analyses for proposed indication.

The FDA has rejected Pfizer’s supplemental new drug application to expand the use of tofacitinib citrate (Xeljanz).

Pfizer sought to expand the use of Xeljanz, now used as a treatment for rheumatoid arthritis, to treat moderate to severe plaque psoriasis in adult patients.

The FDA’s complete response letter, which was sent to Pfizer, is given to a company when a product cannot be approved in its present form.

While the FDA did not approve the expanded indication, the administration did provide recommendations, including that Pfizer provide additional safety analyses for the proposed indication.

“Pfizer remains committed to Xeljanz based on the strength of the clinical data for the treatment of psoriasis,” said Kenneth Verburg, senior vice president and head of global medicines development, Global Innovative Pharma Business, in a press release. “It is our goal to work closely with the FDA to understand and address their comments about our filing for the use of Xeljanz in patients with chronic plaque psoriasis.”

Adverse effects related to Xeljanz include upper respiratory tract infection, headache, diarrhea, and nasal congestion.

Related Videos
Image Credit: SciePro - stock.adobe.com
Pharmacist selling medications in the pharmacy | Image Credit: rh2010 - stock.adobe.com
Atopic dermatitis on a patient's hand -- Image credit: Ольга Тернавская | stock.adobe.com
biosimilar word or concept represented by wooden letter tiles on a wooden table with glasses and a book | Image Credit: lexiconimages - stock.adobe.com
Image credit: alicja neumiler | stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Image credit: Krakenimages.com | stock.adobe.com
Human brain digital illustration. Electrical activity, flashes, and lightning on a blue background. | Image Credit: Siarhei - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.